Drug
Vy7523
Vy7523: highest development phase Phase 1/2, developed by Voyager Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Voyager Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VY7523 NCT06874621 | Phase 1/2 | Alzheimer's Disease (AD) |
Latest
No recent events.
Follow Vy7523 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.